Bio-Techne
TECH
$54.00
-0.04%
Bio-Techne Corp. is a life sciences manufacturer that supplies critical consumables and instruments to pharmaceutical, biotechnology, academic, and diagnostic markets globally. The company operates as a key supplier in the biotechnology sector, with a distinct two-segment structure focused on protein sciences (approximately 75% of revenue) and diagnostics and genomics (25%). The current investor narrative is dominated by the stock's significant price volatility and underperformance relative to the broader market, as recent headlines highlight a challenging period for the company amidst a broader market rally, suggesting investor concerns over its growth trajectory and competitive positioning within the life sciences tools industry.…
TECH
Bio-Techne
$54.00
Investment Opinion: Should I buy TECH Today?
Hold. The stock presents a high-risk, high-potential-reward scenario where the compelling valuation case (if forward estimates are met) is currently outweighed by deteriorating fundamentals and negative price momentum.
The primary valuation metric, the forward P/E of 25.8x, is reasonable for a life sciences tools company if it can deliver the analyst-projected $2.66 EPS, representing significant growth from the TTM EPS of $0.48. However, supporting this requires a reversal of the -0.39% YoY revenue decline and an expansion from the thin 6.02% net margin. The stock trades at a premium P/S of 6.64, and the negative PEG ratio of -1.97 is a major red flag, indicating the market does not believe in the growth needed to justify the multiple.
The thesis would upgrade to a Buy if the company demonstrates a clear return to revenue growth (e.g., >5% YoY) in the next quarter, stabilizing gross margins above 65%, and the stock holds above its recent low of $43.20, confirming a bottom. It would downgrade to a Sell if revenue declines accelerate beyond -2% YoY, forward EPS estimates are cut, or the stock breaks decisively below $43 support. Currently, the stock is fairly valued to slightly overvalued relative to its near-term fundamentals, but potentially undervalued if the forward earnings projection is accurate.
Sign up to view all
TECH 12-Month Price Forecast
The investment case for TECH hinges entirely on a successful pivot from stagnation to growth to justify its forward valuation. The base case of range-bound trading is most probable, given the lack of near-term catalysts for the core business and the stock's technical damage. The substantial gap between trailing (110.4x) and forward (25.8x) P/E creates binary risk: achievement of forward EPS would be highly accretive, while a miss would be catastrophic. The stance would upgrade to bullish on confirmation of revenue growth and technical stabilization above $60. It would turn bearish on a breakdown below $43, which would signal the growth thesis has broken.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Bio-Techne's 12-month outlook, with a consensus price target around $70.20 and implied upside of +30.0% versus the current price.
Average Target
$70.20
6 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
6
covering this stock
Price Range
$43 - $70
Analyst target range
A modest group of six analysts cover the stock, indicating solid institutional interest. The consensus sentiment leans bullish, with recent ratings from firms like Citigroup, UBS, and Wells Fargo maintaining 'Buy' or 'Overweight' equivalents, though Stifel and Evercore ISI have 'Hold' or 'In Line' ratings. The average revenue estimate for the coming period is $1.56 billion, with EPS estimates averaging $2.66, ranging from $2.62 to $2.72. The average target price is not explicitly provided in the data, but the implied upside or downside cannot be calculated without it; however, the presence of multiple 'Buy' ratings suggests analysts see a path to recovery. The target price range and the assumptions behind the high and low targets are not specified in the provided data. The recent rating actions show stability, with no downgrades in the latest batch from early February 2026, and one revision from Evercore ISI moving from 'Outperform' to 'In Line' in January. The relatively small analyst pool and the mix of ratings signal moderate conviction with some divergence in views on the company's near-term prospects.
Bulls vs Bears: TECH Investment Factors
The evidence currently favors the bear case, primarily due to the stark disconnect between the stock's extremely high trailing valuation (110.4x P/E) and its stalled revenue growth and weak profitability metrics. While the balance sheet is strong and analysts project an earnings recovery, the technical price action and fundamental underperformance are powerful counter-arguments. The single most important tension in the investment debate is whether the projected forward EPS of $2.66 is achievable. If the company can deliver on these earnings estimates, the stock appears undervalued at a 25.8x forward P/E. However, if revenue continues to stagnate or decline, compressing margins further, the forward estimates will prove overly optimistic, and the stock's high multiple will contract sharply.
Bullish
- Strong Balance Sheet & Cash Flow: The company maintains a robust financial position with a strong current ratio of 3.46 and a low debt-to-equity ratio of 0.23. Annual free cash flow of $223 million supports the dividend and provides operational flexibility.
- Analyst EPS Growth Projection: Analysts project a significant earnings recovery, with forward EPS estimated at $2.66, implying a forward P/E of 25.8x. This is a steep drop from the trailing P/E of 110.4x, signaling a potential inflection in profitability.
- Deeply Oversold Technical Condition: Trading at $53.18, the stock is near its 52-week low of $43.20, representing just 26% of its annual range. This extreme oversold condition, coupled with a high short interest ratio of 4.89, sets up a potential technical rebound on any positive catalyst.
- Consensus Analyst Bullish Sentiment: Coverage from six major firms includes multiple 'Buy' ratings (Citigroup, UBS, Wells Fargo). This institutional support, despite recent weakness, suggests a belief in the company's long-term fundamentals and recovery path.
Bearish
- Stalled Revenue Growth: The latest quarterly revenue of $295.9M shows a year-over-year decline of 0.39%, and quarterly revenue has been inconsistent. The core Protein Sciences segment (75% of sales) is facing clear headwinds in research funding.
- Extremely High Trailing Valuation: The trailing P/E of 110.4x is exceptionally high for a company with stagnant growth and a net margin of just 6.02%. This valuation is near historical highs and appears disconnected from current fundamentals.
- Severe Underperformance & Negative Momentum: The stock is down 10.85% YTD and 13.78% over six months, dramatically underperforming the S&P 500 (+11.02% YTD). Its 1-month relative strength of -10.78% confirms severe stock-specific negative momentum.
- Poor Capital Efficiency Metrics: Return on Equity is a low 3.83% and Return on Assets is 7.45%, indicating inefficient use of shareholder capital. The operating margin of 8.38% shows significant expense leverage challenges.
TECH Technical Analysis
The prevailing price trend for TECH is a pronounced downtrend, with the stock down 13.78% over the past six months and 10.85% year-to-date as of June 4, 2026, starkly underperforming the S&P 500 which gained 11.02% YTD. The stock is currently trading at $53.18, which is near the lower end of its 52-week range of $43.20 to $72.16, positioning it at approximately 26% of its annual range. This proximity to the 52-week low suggests the stock is in deeply oversold territory, potentially presenting a value opportunity but also signaling persistent negative momentum and a lack of bullish catalysts. Recent short-term momentum shows continued weakness, with the stock declining 6.18% over the past month and 1.32% over the past three months, both periods where the S&P 500 posted gains of 4.6% and 12.6%, respectively. This divergence from the market indicates severe stock-specific headwinds, with the 1-month relative strength of -10.775% confirming the stock's significant underperformance. The key technical levels are clear: immediate resistance lies near the 52-week high of $72.16, while support is at the 52-week low of $43.20. A sustained breakdown below $43.20 would signal a continuation of the bearish trend, while a recovery above the $60 level could suggest stabilization. The stock's beta of 1.405 indicates it is approximately 40% more volatile than the broader market, which, combined with a high short interest ratio of 4.89, suggests elevated risk and potential for sharp moves on any positive news.
Beta
1.36
1.36x market volatility
Max Drawdown
-39.3%
Largest decline past year
52-Week Range
$43-$72
Price range past year
Annual Return
+4.8%
Cumulative gain past year
| Period | TECH Return | S&P 500 |
|---|---|---|
| 1m | +20.3% | -0.1% |
| 3m | +6.2% | +12.0% |
| 6m | -7.7% | +8.8% |
| 1y | +4.8% | +22.9% |
| ytd | -9.5% | +8.8% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
TECH Fundamental Analysis
Revenue growth has stalled, with the most recent quarterly revenue of $295.9 million representing a slight year-over-year decline of 0.39%. The quarterly trend shows inconsistency, with revenue of $286.6M, $316.2M, and $297.0M in the preceding quarters, indicating a challenging growth environment. The core Protein Sciences segment, representing about 75% of sales, is likely facing headwinds in the broader life sciences research funding environment. Profitability remains positive but is under pressure; the company reported net income of $38.0M for the quarter ending December 2025, with a gross margin of 64.65%, down from 65.65% in the prior quarter. The trailing twelve-month net margin is a thin 6.02%, and operating margin is 8.38%, reflecting significant operating expense leverage challenges. The balance sheet and cash flow position provide some stability; the company maintains a strong current ratio of 3.46 and a manageable debt-to-equity ratio of 0.23. Free cash flow over the trailing twelve months is a healthy $223.0 million, providing ample liquidity for operations and its dividend, which has a payout ratio of 68.7%. However, return on equity is low at 3.83%, and return on assets is 7.45%, indicating inefficient use of shareholder capital and assets in the current operating climate.
Quarterly Revenue
$295877000.0B
2025-12
Revenue YoY Growth
+0.00%
YoY Comparison
Gross Margin
+0.64%
Latest Quarter
Free Cash Flow
$223020000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is TECH Overvalued?
Given the positive net income, the primary valuation metric is the Price-to-Earnings (PE) ratio. The trailing PE ratio is extremely elevated at 110.4x, while the forward PE is a more reasonable 25.8x. This massive gap implies the market expects a significant recovery in earnings over the next year, as the forward multiple is based on estimated EPS of $2.66. Compared to industry averages, the stock trades at a premium on a Price-to-Sales basis, with a PS ratio of 6.64 versus a typical biotechnology tools peer average in the mid-single digits, though a direct industry average is not provided in the data. The forward PE of 25.8x suggests the premium is predicated on future earnings growth, but the negative PEG ratio of -1.97 signals that growth expectations, as implied by the market, are negative or not aligned with the high multiple. Historically, the current trailing PE of 110.4x is near the top of its own range over the past several quarters, which have fluctuated widely from negative values to over 110x. Trading near historical highs on a trailing basis, despite the sharp price decline, indicates the market is still pricing in a high multiple on depressed earnings, reflecting either an expectation of a rapid profit rebound or a valuation that remains stretched relative to current fundamentals.
PE
110.4x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range -113x~293x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
38.7x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks center on the company's ability to translate high gross margins into bottom-line profits. With a trailing net margin of only 6.02% and an operating margin of 8.38%, there is significant operating expense leverage risk. The quarterly revenue decline of 0.39% YoY and inconsistent quarterly sales ($286.6M to $316.2M) highlight vulnerability in the core Protein Sciences segment, which comprises 75% of revenue. This concentration creates a single-point-of-failure risk if research funding in biopharma remains constrained. While free cash flow is healthy at $223M, the dividend payout ratio of 68.7% leaves limited room for error if earnings deteriorate.
Market & Competitive Risks are amplified by the stock's premium valuation. The Price-to-Sales ratio of 6.64 is elevated compared to typical biotech tools peers, creating valuation compression risk if growth does not materialize. The stock's beta of 1.405 indicates it is 40% more volatile than the market, making it highly sensitive to sector rotations away from growth or healthcare. Competitive disruption in the life sciences tools space and potential pricing pressure are persistent threats. Recent news highlights a market rally driven by AI and tech, from which TECH has been completely excluded, underscoring its current irrelevance to broader market trends.
The Worst-Case Scenario involves a continuation of the revenue decline coupled with margin erosion, leading to a miss on the forward EPS estimate of $2.66. This would shatter the forward P/E re-rating thesis and trigger multiple compression. A reversion to the 52-week low of $43.20, a level tested in May 2026, represents a realistic downside of approximately -19% from the current price of $53.18. Given the stock's high volatility and negative momentum, a breach of that support could lead to a test of levels not seen in several years, potentially resulting in a total drawdown exceeding 30-35% from current levels as the market re-prices the stock for no growth.
FAQ
The key risks are, in order of severity: 1) Execution & Growth Risk: Failure to return to revenue growth and achieve the projected $2.66 EPS, which would cause the forward P/E thesis to collapse. Recent quarterly revenue decline of -0.39% highlights this. 2) Valuation Compression Risk: The high trailing P/E of 110.4x and P/S of 6.64 leave the stock vulnerable to multiple contraction if growth remains elusive. 3) Market & Sentiment Risk: The stock has severely underperformed the market (-10.85% YTD vs. SPY +11.02%) and has a high beta of 1.405, making it volatile and prone to being overlooked in rallies. 4) Operational Risk: Low return metrics (ROE 3.83%, Operating Margin 8.38%) indicate inefficiency and vulnerability to further margin pressure.
Our 12-month forecast outlines three scenarios. The Base Case (50% probability) sees the stock trading between $55 and $65, as flattish revenue and meeting low-end EPS estimates ($2.62) lead to range-bound action. The Bull Case (30% probability) projects a rally to $68-$72, driven by a return to revenue growth, meeting the $2.66+ EPS estimate, and a positive market re-rating. The Bear Case (20% probability) warns of a decline to $43-$50, triggered by worsening revenue trends, an earnings miss, and a break below key technical support. The base case is most likely, implying limited near-term upside from the current ~$53 price until growth visibility improves.
TECH's valuation is a tale of two metrics, creating confusion. On a trailing basis, it appears extremely overvalued with a P/E of 110.4x and a P/S of 6.64, which is high for a company with stagnant growth. However, based on forward analyst estimates of $2.66 EPS, the forward P/E of 25.8x looks reasonable for the sector. The market is thus pricing in a significant earnings recovery that has not yet occurred. The negative PEG ratio of -1.97 signals the market's skepticism about future growth. Currently, the stock is fairly valued to slightly overvalued relative to its demonstrated fundamentals, but potentially undervalued if the forward earnings projection is accurate—a big 'if' given recent trends.
TECH is a high-risk, high-potential-reward investment that is not a good buy for most investors at this moment. For aggressive investors with a high risk tolerance and a long time horizon, the current price near 52-week lows and the reasonable forward P/E of 25.8x (if estimates are met) could present an entry point. However, the deteriorating fundamentals, including a -0.39% YoY revenue decline and poor capital efficiency (ROE 3.83%), pose significant risks. It could be a good buy for a contrarian if the next earnings report shows a return to growth, but currently, the evidence supports a 'Hold' rating until that catalyst materializes.
TECH is unsuitable for short-term trading due to its high volatility (beta 1.405), negative momentum, and lack of near-term catalysts. The 0.62% dividend yield does not provide meaningful income for a total return strategy. The investment thesis is fundamentally a long-term turnaround story, requiring at least 12-18 months for the company to demonstrate a sustained recovery in its core Protein Sciences segment and for the forward earnings estimates to be validated or revised. Therefore, it is only suitable for long-term, patient investors who can tolerate significant price swings and are betting on a cyclical recovery in biopharma research budgets.